SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — John Locke — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJohn Locke
Date of birth1632-09-08
IdentifiersMRN HR-EN001-SYN-TD; SSN (made up) 000-01-8305
Document date1692-10-22
AuthorPrudence Hartwell-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Asthma review two weeks after a cold with a yellow-zone flare. [S]

History of Present Illness

Mr. Locke returns two weeks after his sick visit for a cold that triggered a yellow-zone flare. He took up to 11 inhalations of budesonide-formoterol on the worst day and never needed prednisolone. His peak flow climbed back above 400 L/min by the fifth day and has been 420 to 440 since. The cold cleared in about a week, and he stopped acetaminophen after four days. The review planned for one week after the sick visit did not take place: the clinic's first slot was today. He now needs his reliever about once a week, sleeps through the night, and has no side effects from tiotropium (no dry mouth, difficulty passing urine, or eye pain). The open fires remain out of use. He would like his first zoster vaccine today. [S]

ElementDetail
FlareYellow zone with a cold; managed by the action plan without prednisolone
Peak flowBack to 420 to 440 L/min; 430 in clinic today
Reliever useAbout once a week
TiotropiumFour months; no side effects
Asthma Control Test21

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; energy back to normal
RespiratoryNegativeNo cough, wheeze, or night waking now; breathless only on steep hills
GenitourinaryNegativeNo difficulty passing urine
EyesNegativeNo eye pain or blurred vision

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometryTwo puffs every 4 hours as neededRespiratory tract route1692-03-12 to 1692-03-26completedS
Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a dayTwo inhalations twice daily plus one as needed; no more than 12 a dayRespiratory tract route1692-03-26activeS
Tiotropium 2.5 mcg/actuation soft-mist inhaler, two inhalations once daily (add-on long-acting muscarinic antagonist, GINA step 5)Two inhalations once a dayRespiratory tract route1692-06-18activeS
Acetaminophen 500 mg oral tablet, one or two tablets every 6 hours as needed for aches or fever, no more than 3 g a dayOne or two tablets every 6 hours as needed; no more than six tablets a dayOral route1692-10-08 to 1692-10-22completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1692-10-22Body height178cmS
1692-10-22Body weight62.8kgS
1692-10-22Body mass index (BMI) [Ratio]19.8kg/m2S
1692-10-22Systolic blood pressure118mm[Hg]S
1692-10-22Diastolic blood pressure72mm[Hg]S
1692-10-22Heart rate74/minS
1692-10-22Respiratory rate16/minS
1692-10-22Body temperature36.5CelS
1692-10-22Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1692-10-22Maximum expiratory gas flow Respiratory system airway by Peak flow meter430L/min80 percent of his personal best of 440 L/minNormalS
1692-10-22Total score [ACT]21{score}S

Physical Exam

Vital signs recorded on 1692-10-22; see the Vital Signs section. [S]

SystemFinding
GeneralWell
RespiratoryClear on quiet and forced breathing; oxygen saturation 97 percent
MouthNo candidiasis

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic cough with wheeze and breathlessness since his late thirties, worse every winter and within a day of any stay in the city or by an open fire, better in warm weather and country air; night cough two or three times a week this winter; under evaluationresolvedconfirmed R05.3S — Synthetic presenting problem echoing his documented lifelong cough and breathlessness in London's coal smoke; superseded by the diagnosis at the second visit.
Long exposure to urban air pollution (decades in a large city with heavy traffic and coal and wood burning) and to indoor solid-fuel smoke from open coal and wood fires at homeactiveconfirmed Z77.110S — Synthetic modern exposure echoing the coal smoke that he, Sydenham, and Lady Masham blamed for his cough; no historical level of exposure is asserted.
Asthma with persistent airflow limitation, type 2 (eosinophilic) phenotype, in a never-smoker: post-bronchodilator FEV1/FVC 0.62, FEV1 62 percent predicted rising 380 mL after albuterol, FeNO 41 ppb, eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, normal DLCO, no emphysema on CT; aggravated by air pollution and indoor smoke; not COPDactiveconfirmed J45.40S — Synthetic modern diagnosis. His lifelong cough and breathlessness worse in coal smoke are documented (D); calling them asthma is a modern retrospective reading (R).
Acute viral upper respiratory infection (common cold) with a yellow-zone asthma flare: peak flow 68 percent of personal best, managed with extra as-needed budesonide-formoterol by his action plan, without oral corticosteroids; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness at an unscheduled visit; it echoes, without asserting, his documented autumn chest troubles (CLM-0014).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyAsthma Control TestEvery visitCompleted today21: well controlled
ImagingPeak expiratory flowAt each visit after a flare, and at home with symptomsCompleted today430 L/min in clinic, 98 percent of his best
SurveyReview within one week after a flareWithin one week of any exacerbationDeferredMissed: the one-week review planned at the sick visit was not booked because no slot was free, and no telephone check was arranged. No harm resulted: his diary shows the peak flow back above 400 L/min by the fifth day without prednisolone. Corrective action: the clinic now books a review within one week, by telephone if no slot is free, whenever he calls or is seen for a flare, and this is written into his care plan
SurveyReview 1 to 3 months after a controller change, with an Asthma Control Test1 to 3 months after starting or changing controller treatmentDeferredPartly missed: the twelve-week plan set the full review with an Asthma Control Test at four months, beyond the protocol's 1 to 3 months. The preventive visit at 13 weeks reviewed his symptoms, reliever use, and side effects, but no Asthma Control Test was recorded until today. No harm: he was well controlled at that visit and today. Corrective action: an Asthma Control Test is recorded at any visit where asthma is reviewed
ExaminationInhaler technique with his own devicesEvery visitCompleted todayBoth inhalers used correctly
Medication safetyAdherence and reliever useEvery visitCompleted todayNo missed doses since the flare; reliever about once a week
Medication safetyTiotropium side effects (dry mouth, urinary retention, angle-closure glaucoma symptoms)After starting and at each visitCompleted todayNone
SurveyExacerbation historyEvery visitCompleted todayOne yellow-zone flare with a cold; no oral corticosteroids, emergency visits, or admissions
Self-managementTrigger and exposure review: indoor solid-fuel smoke, outdoor air pollution and air quality alerts, tobacco and vaping, occupational exposures, allergensEvery visitCompleted todayOpen fires out of use; HEPA air cleaners running; air quality index checked before city trips; no new exposures
Self-managementSmoking and vaping statusEvery visitCompleted todayNever smoker; no vaping; no secondhand smoke
Self-managementWritten asthma action planEvery visit and after every flareCompleted todayReviewed after the flare; he used it correctly; unchanged
Medication safetyStep-up and step-down assessmentEvery visitCompleted todayWell controlled at step 5 (add-on tiotropium); no step-down so soon after a flare; reconsider after three months of good control
ImagingSpirometryEvery 1 to 2 years once stableUp to dateLast done four months ago; next within a year
ImagingFeNOTo monitor inhaled-corticosteroid response when neededNot indicatedLow on treatment four months ago; control is good
ExaminationComorbidity surveillanceAt diagnosis and at least yearlyUp to dateScreened at diagnosis; PHQ-2 0 at the preventive visit
Self-managementVaccination statusYearlyCompleted todayInfluenza, COVID-19, and RSV vaccines given five weeks ago; zoster dose 1 today
Medication safetyBiologic candidacyWhen asthma is severe and uncontrolled despite optimized step 4 to 5 treatment with confirmed adherence and techniqueNot indicatedNo exacerbations needing oral corticosteroids and not uncontrolled on optimized treatment

Goal progress:

Immunizations given today: Recombinant zoster vaccine, dose 1 of 2 [S]

Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022); WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021); Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020); AQI Basics (2026); Air Cleaners and Air Filters in the Home (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Asthma review in three months; zoster dose 2 in two to six months; spirometry within a year of the last. [S]